Response to NHS’s Proposed MedTech Pathway

Ve3’s Strategic Feedback On Integrated, Rules-based Medtech Pathway

In our submission, we emphasized the importance of robust data collection for horizon scanning and advocated for a shared understanding of MedTech value early in the product development cycle. We believe that by prioritizing real-world evidence, the pathway can more accurately reflect the true impact of technologies on patient care and the healthcare system.

We also recommended continuous improvement mechanisms and sustainable funding to keep the pathway adaptable and effective over time. Furthermore, we stressed the need for international collaboration to streamline regulatory processes, helping to bring innovative technologies to market more quickly. Download our full response to learn more about our vision for a better healthcare future. Join us in our mission to advance MedTech and improve lives.

Download Our Full Response Now

View PDF

Read the Latest Insights and Thought Leadership

Stay current with the strategies, trends, and technologies defining the next era of digital excellence

Supply Chain
March 16, 2026

Agentic AI in the Enterprise: From Experiments to Production Systems

Siddharth Sagar
Read More
Supply Chain
March 10, 2026

Data Quality Tools 2026: The Complete Buyer’s Guide to Trusted Data

Ritesh Nandurkar
Read More
Supply Chain
March 9, 2026

Why Query Tracing Is the Missing Layer in Enterprise AI Observability

Akanksha Chakure
Read More
Supply Chain
March 9, 2026

How Chain-of-Thought Improves Enterprise AI Responses

Gourav Roy
Read More
Supply Chain
December 26, 2025

A Practical Guide to HL7/FHIR API Integration: Architecture, Workflows & Best Practices

Prabal Laad
Read More
Supply Chain
December 12, 2025

Supply Chain Visibility & Orchestration: The New Operating Model for Modern Enterprises

Prabal Laad
Read More

Ready to transform your data?

Let's discuss how our data analytics expertise can drive growth and innovation for your business.

Let's Connect →
  • © 2026 VE3. All rights reserved.